Literature DB >> 23520363

Limbic encephalitis associated with elevated antithyroid antibodies.

Yael Hacohen1, Sonia Joseph2, Rachel Kneen3, Paul Eunson4, Jean-Pierre Lin5, Angela Vincent6, Ming Lim7.   

Abstract

Immune-mediated limbic encephalitis affects both adults and children. Patients typically present with seizures, memory problems, and imaging changes in the medial temporal lobes. Both paraneoplastic and nonparaneoplastic forms have been described in which the antibody to the voltage-gated potassium channel-complex associated protein, leucine-rich glioma-inactivated 1, is most commonly reported. Elevated antithyroid antibodies have also been reported in a range of neurological syndromes with encephalopathy, such as limbic encephalitis, often collectively termed Hashimoto encephalopathy, a condition whereby corticosteroids responsiveness with a complete recovery is commonly observed. Here we describe 3 children presenting with limbic encephalitis with elevated thyroid antibodies that did not respond to corticosteroids alone and required more aggressive immunotherapy, mirroring the slower treatment response that is more frequently seen in other immune-mediated forms of limbic encephalitis.
© The Author(s) 2013.

Entities:  

Keywords:  Hashimoto; autoantibodies; encephalitis; encephalopathy; epilepsy; limbic system

Mesh:

Substances:

Year:  2013        PMID: 23520363     DOI: 10.1177/0883073813480392

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  1 in total

1.  Clinical features, investigations, and outcomes of pediatric limbic encephalitis: A multicenter study.

Authors:  Saraswathy Sabanathan; Omar Abdel-Mannan; Kshitij Mankad; Ata Siddiqui; Krishna Das; Lucinda Carr; Christin Eltze; Michael Eyre; Jon Gadian; Cheryl Hemingway; Marios Kaliakatsos; Rachel Kneen; Deepa Krishnakumar; Bryan Lynch; Amitav Parida; Thomas Rossor; Micheal Taylor; Evangeline Wassmer; Sukhvir Wright; Ming Lim; Yael Hacohen
Journal:  Ann Clin Transl Neurol       Date:  2022-01-11       Impact factor: 4.511

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.